TW202137986A - 治療失眠之方法 - Google Patents

治療失眠之方法 Download PDF

Info

Publication number
TW202137986A
TW202137986A TW109145085A TW109145085A TW202137986A TW 202137986 A TW202137986 A TW 202137986A TW 109145085 A TW109145085 A TW 109145085A TW 109145085 A TW109145085 A TW 109145085A TW 202137986 A TW202137986 A TW 202137986A
Authority
TW
Taiwan
Prior art keywords
child
pharmaceutically acceptable
pugh
acceptable salt
dose
Prior art date
Application number
TW109145085A
Other languages
English (en)
Chinese (zh)
Inventor
瑪格麗特 莫琳
伊瑄妮 蘭德瑞
安德魯 沙特琳
Original Assignee
日商衛材R&D企管股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商衛材R&D企管股份有限公司 filed Critical 日商衛材R&D企管股份有限公司
Publication of TW202137986A publication Critical patent/TW202137986A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
TW109145085A 2019-12-20 2020-12-18 治療失眠之方法 TW202137986A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962951638P 2019-12-20 2019-12-20
US62/951,638 2019-12-20

Publications (1)

Publication Number Publication Date
TW202137986A true TW202137986A (zh) 2021-10-16

Family

ID=74191874

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109145085A TW202137986A (zh) 2019-12-20 2020-12-18 治療失眠之方法

Country Status (11)

Country Link
US (1) US20230051268A1 (https=)
EP (1) EP4076463A1 (https=)
JP (2) JP2023508011A (https=)
KR (1) KR20220119065A (https=)
CN (1) CN115003305A (https=)
AU (1) AU2020408557A1 (https=)
BR (1) BR112022012246A2 (https=)
CA (1) CA3165481A1 (https=)
MX (1) MX2022007304A (https=)
TW (1) TW202137986A (https=)
WO (1) WO2021127359A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024305901A1 (en) * 2023-06-29 2026-02-12 Janssen Pharmaceutica Nv Method of treating depression using seltorexant

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0828751A4 (en) 1995-05-05 1999-01-20 Human Genome Sciences Inc HUMAN NEUROPEPTIDE RECEPTOR
US6309854B1 (en) 1996-12-17 2001-10-30 Smithkline Beecham Corporation Polynucleotides encoding ligands of the neuropeptide receptor HFGAN72
US5935814A (en) 1997-04-30 1999-08-10 Smithkline Beecham Corporation Polynucleotides encoding HFGAN72Y receptor
US6020157A (en) 1997-04-30 2000-02-01 Smithkline Beecham Corporation Polynucleotides encoding HFGAN72X receptor
US6166193A (en) 1997-07-25 2000-12-26 Board Of Regents, University Of Texas System Polynucleotides encoding MY1 receptor
AU2011304285B2 (en) 2010-09-22 2015-01-29 Eisai R&D Management Co., Ltd. Cyclopropane compound
BR112014019909B1 (pt) 2012-02-17 2020-01-28 Eisai R&D Man Co Ltd processo para produção de compostos úteis como antagonistas do receptor de orexina-2
ES2843952T3 (es) 2014-10-23 2021-07-21 Eisai R&D Man Co Ltd Composiciones para tratar el insomnio
CA3051830A1 (en) * 2017-01-27 2018-08-02 Neurocrine Bioscienes, Inc. Methods for the administration of certain vmat2 inhibitors

Also Published As

Publication number Publication date
CN115003305A (zh) 2022-09-02
BR112022012246A2 (pt) 2022-08-30
JP2025160480A (ja) 2025-10-22
EP4076463A1 (en) 2022-10-26
JP2023508011A (ja) 2023-02-28
CA3165481A1 (en) 2021-06-24
WO2021127359A1 (en) 2021-06-24
KR20220119065A (ko) 2022-08-26
MX2022007304A (es) 2022-08-22
AU2020408557A1 (en) 2022-08-11
US20230051268A1 (en) 2023-02-16

Similar Documents

Publication Publication Date Title
TWI795359B (zh) 晝夜節律睡眠障礙之治療方法
TW202131910A (zh) 使用mtorc1調節劑的治療方法
JP2025160480A (ja) 不眠症を治療するためのレンボレキサントの使用
AU2026201519A1 (en) Lemborexant for treating sleep issues
RU2844395C2 (ru) Лемборексант для лечения проблем со сном
EP3989976A1 (en) Lemborexant for treating sleep issues
US11529358B2 (en) Treatment of conditions associated with myotonic dystrophy
Barrouq et al. Escalating BMI Associated With the Complex Pharmacology of Propranolol: A Case Report
WO2020263331A1 (en) Lemborexant for treating sleep issues
JP2025116005A (ja) 睡眠問題の治療のためのレンボレキサント
WO2023143364A1 (zh) 一种血小板生成素受体激动剂的给药方案
WO2023007320A1 (en) Lemborexant for use in methods of treating irregular sleep-wake rhythm disorder and circadian rhythm sleep disorders associated with neurodegenerative diseases
WO2026052068A1 (zh) 药物组合物的用途
Ya et al. Aripiprazole-induced parkinsonism in diagnosed with bipolar disorder: a case report
CN101827597A (zh) 睡眠障碍的治疗
EA051682B1 (ru) Изопропиловый эфир [((1r,2s,5r)-2-изопропил-5-метилциклогексанкарбонил)амино]уксусной кислоты для лечения хронического кашля
Tremor NEUROLOGICAL SLEEP DISORDERS
NZ787958A (en) Methods of treating circadian rhythm sleep disorders
HK40007283A (en) Methods of treating circadian rhythm sleep disorders